Contents

§6. Cephem Antibiotics

New Aminothiazole Cephalosporins with 3-Pyridiniumthiomethyl Substituents
T. Tsuruoka et al. ................................................................. 877

In vitro and in vivo Antibacterial Activity of M 14643, a New Semisynthetic Cephalosporin
H. Inaba et al. ................................................................. 879

In vitro and in vivo Antibacterial Activity of M 14638, a New Semisynthetic Cephalosporin
H. Mochizuki et al. ................................................................. 881

Antibacterial Activity of CGP 31 523 A, a New Parenteral Cephalosporin
W. Tosch et al. ................................................................. 883

Chemotherapeutic Efficacy of CGP 31 523 A, a New Cephalosporin Antibiotic, in vivo
O. Zak et al. ................................................................. 885

The in vitro and in vivo Antibacterial Activities of L-105, a New Parenteral Cephalosporin
M. Otsuki et al. ................................................................. 887

Bactericidal Activity of L-105, a New Cephalosporin
M. Hikida et al. ................................................................. 889

Antimicrobial Activity and Pharmacokinetics of L-105, a New Cephem Antibiotic Agent
M. Tomisawa et al. ................................................................. 891

Pharmacokinetics of L-105 in Patients with Renal Insufficiency
A. Mizuno et al. ................................................................. 893

Laboratory and Clinical Studies on L-105, a New Cephem Antibiotic
Y. Shigeno et al. ................................................................. 895

In vitro Antibacterial Activity of L-105, a New Cephalosporin, against Respiratory Pathogenic Organisms, and Its Pharmacokinetic Properties
A. Takahashi et al. ................................................................. 897

L-105: In vitro Antimicrobial Activity and Therapeutic Efficacy on Lower Respiratory Infections
A. Watanabe et al. ................................................................. 899

Fundamental and Clinical Studies of L-105 in Ophthalmologic Field
M. Ooishi et al. ................................................................. 901

Biliary Excretion, Tissue Concentration in Gallbladder, and Clinical Effects in Patients Treated with L-105
N. Kobayashi et al. ................................................................. 903

Antimicrobial Activity and Clinical Efficacy of L-105
F. Miki et al. ................................................................. 905

Fundamental and Clinical Studies of L-105 in Obstetrics and Gynecology
N. Cho et al. ................................................................. 907
Safety and Pharmacokinetics of Intramuscularly Administered Cefpimizole (Ajinomoto-1370, Upjohn U-63196E) in Normal Human Volunteers
E. Novak et al. .................................................. 909

Clinical Evaluation of AC-1370 in Complicated Urinary Tract Infections: A Double-blind Controlled Study with Cefoperazone
S. Nakamura et al. ............................................. 910

Antibacterial Activity of Ceftirome (HR 810) against Pathogens Involved in STD and Stability towards β-Lactamases Produced by *Neisseria gonorrhoeae* and *Haemophilus ducreyi*
E. Schrinner et al. ............................................ 912

The *in vitro* Activity of HR 810 Compared with Four Other β-Lactam Antibiotics
E. Canton et al. .................................................. 914

*In vitro* Activity of HR 810 Compared with Ceftazidime against Aerobic Gram-negative Bacteria
L. Steele-Moore and W. Holloway .......................... 916

HR 810 and BMY-28142, Two New Cephalosporins with Broad-spectrum Activity: An *in vitro* Comparison with Other β-Lactam Antibiotics
A. M. Clarke et al. ............................................. 917

Comparative *in vitro* Activity of BMY-28142 Alone and in Combination with Amikacin against Organisms Relatively Resistant to Gentamicin
D. Gerding et al. .................................................. 919

Disposition of BMY-28142 in Cynomolgus Monkeys and Beagle Dogs
R. H. Barbhaiya et al. ......................................... 921

Antibacterial Activity of Cefodizime (HR 221)
W. Stille and S. Spieler ....................................... 923

The Interactions of Cefodizime with β-Lactamases
R. Labia et al. .................................................... 925

*In vitro* Antibacterial Activity of a New Aminothiazolyl-oximino Cephalosporin: Cefodizime (HR 221) against 323 Gram-negative Rods Isolates:
Comparison with Cefotiam, Cefoperazone, Cefotetan and Cefotaxime
P. Le Noc et al. ................................................... 927

*In vitro* Antimicrobial Activity of Cefodizime (HR 221)
A. Raimondi et al. ............................................. 929

Stimulation of Lymphocyte Cell Growth *in vitro* by the Cephalosporin-derivatives Cefodizime (HR 221) and Cefotaxime
W. E. G. Müller and G. Seibert ................................ 931

Influence of Cefodizime (HR 221) on the Immune System
M. Limbert et al. .................................................. 933

Bactericidal Activity of Cefodizime under Conditions Simulating Serum Pharmacokinetic Parameters
P. M. Shah ........................................................ 935

Cefodizime (HR 221): Pharmacokinetics in Healthy Volunteers after 1 g i.v. Bolus, 1 g i.m.
G. Humbert et al. .................................................. 937

Concentration of Cefodizime (HR 221), a New Cephalosporin in Urological Tissues
A. Hofstetter et al. ............................................... 939

Cefodizime (HR 221), a New Aminothiazolyl Cephalosporin: First Clinical Results - Multicentric Study
P. Veyssier et al. .................................................. 941
CONTENTS vii

Comparative Therapeutic Effects of Cefodizime and Other Cephalosporins in the Treatment of Experimentally Induced Pneumonia in Mice
N. Klesel et al. ................................................................. 943

A Comparative Study of Ceftazidime with Other Cephalosporins
Jia-Tai Li et al. ................................................................. 945

The Volume of Distribution of Ceftazidime in Normal, Fractured and Infected Bone
F. M. Anderson et al. .......................................................... 947

A Pharmacokinetic Study on Ceftazidime and Cefoperazone in Healthy Chinese Volunteers
Jia-Tai Li et al. ................................................................. 949

Pharmacokinetics of Ceftazidime in Normal Subjects and Patients with Renal Failure
S. Vulterini et al. ............................................................... 951

Pharmacokinetics of Ceftazidime in Renal Insufficiency and during Haemodialysis
R. V. Dalen et al. ............................................................... 953

Pharmacokinetics and Clinical Use of Ceftazidime in Pediatrics
P. Bégué et al. ................................................................. 955

Comparative Investigation of Serum Bactericidal Kinetics after Application of Ceftazidime and Ceftriaxone
U. Ullmann and M. Erttmann .............................................. 957

Comparative Randomized Blind Study on Ceftazidime vs Ceftazidime + Sisomicin vs Piperacillin + Sisomicin in Pseudomonas Pulmonary Exacerbations in Cystic Fibrosis
R. Padoan et al. ............................................................... 959

Treatment of Serious Infections in a Surgical Intensive Care Unit:
Ceftazidime versus Cefotaxime and Piperacillin
E. Mueller et al. ............................................................... 961

Ceftazidime versus Cefazolin Plus Azlocillin in Therapy of Nosocomial Bronchopulmonary Infections
R. Serafin et al. ............................................................... 963

Clinical and Pharmacokinetic Study of Ceftazidime in the Treatment of Pseudomonas Infections in Intensive-care Patients
R. Rondanelli et al. ........................................................... 968

Combined Action of Ceftazidime with Other Antibiotics and Inhibition of Development of Secondary Resistance
C. Simon and M. Simon ..................................................... 970

Pharmacokinetics of Intravenous Ceftazidime and Aztreonam in Crossover Study in Humans
E. Yamaji et al. ............................................................... 972

Efficacy and Safety of Ceftazidime in the Treatment of Selected Cancer Patients with Serious Infections
O. Quesada et al. ............................................................. 974

Evaluation of Ceftazidime in Pseudomonas Meningitis
C. Ezpeleta et al. ............................................................. 976

Ceftazidime in the Management of Severe Infections
A. Spantideas et al. .......................................................... 978

A Randomized Study of Ceftazidime Monotherapy versus Ceftazidime and Cephalothin in Febrile Neutropenic Patients
R. S. G. Holdrinet et al. ..................................................... 980

Randomized Comparison of Ceftazidime versus Tobramycin Therapy for Gram-negative Burn Wound Infection
H. G. Stiver et al. ............................................................ 982
Evaluation of Ceftriaxone Concentrations in Prostatic Adenoma Tissue after Intravenous Single Dose Administration
R. Oertle et al. .................................................. 984

Distribution of Ceftriaxone in Purulent Peritoneal Fluid, and in Lochia during Puerperium
D. A. Kafetzis et al. .................................................. 986

Ceftriaxone Therapy of Osteomyelitis
A. D. Tice et al. .................................................. 988

Pharmacokinetics of Ceftriaxone in Serum and Gynecological Tissues
P. De Grandi and J.-F. Bauen ........................................ 990

A Multicenter Trial on the Activity of Ceftriaxone in the Treatment of Lower Respiratory Tract Infections
C. Grassi .................................................. 992

Comparative Study between Two Third-generation Cephalosporins (Ceftriaxone-Cefoperazone) in the Treatment of Severe Infectious Diseases
J. P. Ducroix et al. .................................................. 994

The Clinical Effectiveness and Compatibility of Ceftriaxone in Pediatric Surgery
A. F. Schärli and K. Brühlhart ........................................ 996

Comparative Study of Ceftriaxone and Trimethoprim-Sulfamethoxazole for the Treatment of Chancroid in Thailand
D. N. Taylor et al. .................................................. 998

Serum Concentration and Elimination Half-life of Ceftriaxone in Patients with Severe Infections
F. Follath et al. .................................................. 1000

Disposition of Ceftriaxone in Patients with Pleural Effusion
G. Benoni et al. .................................................. 1002

Inpatient-outpatient Treatment of Serious Infections with a Single Daily Dose of Ceftriaxone
L. Jauregui et al. .................................................. 1004

A Comparative Trial of Ceftriaxone versus Cefamandole in the Therapy of Lower Respiratory Tract Infections in Elderly Men
W. C. Graham and R. B. Belshe ..................................... 1006

Cefonicid Pharmacokinetics in Normal Subjects and in Renal Insufficiency
J. P. Fillastre et al. .................................................. 1008

Comparative Clinical Evaluation of Cefonicid in the Treatment of Urinary Tract Infections Caused by Indole-positive Organisms
D. Ziv et al. .................................................. 1010

In vitro Susceptibility of Various Species of Pseudomonas to Cefsulodin
G. Blandino et al. .................................................. 1012

Cefsulodin/Tobramycin as Alternative Therapy for Serious Pseudomonas aeruginosa Infections Where a Penicillin Cannot Be Given
L. Crane et al. .................................................. 1014

In vitro and Clinical Study of Cefsulodin against Pseudomonas and Opportunistic Bacteria
A. Limsuwan et al. .................................................. 1016

Comparative Study of Cefsulodin and Conventional Anti-pseudomonal Therapy in the Treatment of Malignant External Otitis: A Retrospective Analysis
B. R. Meyers et al. .................................................. 1018
Comparative Clinical Evaluation of Cefsulodin/Tobramycin and Ticarcillin/Tobramycin in Serious *Pseudomonas aeruginosa* Infections

L. Crane *et al.* .......................... 1020

Cefpiramide: Antibacterial Activity, β-Lactamase Stability and Disk Diffusion Susceptibility Tests

A. L. Barry *et al.* .......................... 1022

Pharmacokinetics of Cefpiramide after Intravenous Administration

N. Nazari *et al.* .......................... 1024

Open Study of Intravenously Administered Cefpiramide in the Treatment of Bacterial Infections in Hospitalized Patients

N. Nazari *et al.* .......................... 1026

Clinical Evaluation of Cefpiramide in Complicated Urinary Tract Infection by Open Prospective Method

R. Sharifi *et al.* .......................... 1028

*In vitro* Study of the Susceptibility of Fresh Clinical Isolates to the Combination of Cefoperazone Plus Sulbactam

D. Bechard *et al.* .......................... 1030

The Clinical and Experimental Study of the Biliary Excretion of Cefoperazone in Cases with External Biliary Fistula

H. Shimada *et al.* .......................... 1032

Elimination of Fecal Microflora by Cefoperazone Therapy in Patients

E. E. Ohnhaus *et al.* .......................... 1034

Cefoperazone versus Standard Combination Antibiotic Therapy for Gram-negative Pneumonia and Nosocomial Aspiration Pneumonia

R. J. Mangi *et al.* .......................... 1036

Cefoperazone versus Clindamycin Plus Gentamicin for the Treatment of Obstetric and Gynecologic Infections

R. S. Gibbs *et al.* .......................... 1038

Outpatient Cefoperazone Therapy

L. J. Eron *et al.* .......................... 1040

Studies on the Transfer of Cefotaxime into the Cerebrospinal Fluid in the Field of Neurosurgery

M. Sato and K. Echizenya .......................... 1042

Studies on the Concentration of Cefotaxime in Tissues in the Field of Obstetrics and Gynecology

S. Hoshi *et al.* .......................... 1044

Concentrations of Cefotaxime and Desacetylcefotaxime in Synovial Fluid

A. Kazmierczak *et al.* .......................... 1046

Cefotaxime in Serious Infections Caused by Staphylococci

R. Blomer and K. Bruch .......................... 1048

A Single-blind Comparative Study of Parenteral Cefotaxime and Oral Cefalexin in the Treatment of Patients with Uncomplicated, Non-obstructive Urinary Tract Infections Caused by Susceptible Bacteria

O. Shobokshi and Y. Al-Saffi .......................... 1050

Pharmacokinetic Studies of Cefmenoxime and Cefotaxime in Terms of Maternal and Fetal Plasma Concentrations, Placental Transfer, Protein Binding Rate and Tissue Concentration in Pelvic Organs

S. Tanaka *et al.* .......................... 1053

Dynamics of Cefmenoxime Ophthalmic Solution in Ocular Tissues and Its Clinical Application

K. Sasaki *et al.* .......................... 1055
In vitro Antibacterial Activity of β-Lactam Antibiotics
   Yu-kun Liu et al. .................................................. 1057
A Laboratory Assessment of Eight β-Lactamase Stable Cephalosporins
   S. Esposito et al. .................................................. 1059
Susceptibility of Haemophilus influenzae to First, Second, and Third Generation
Cephalosporins
   J. A. Daly et al. ................................................... 1061
The Transfer of Cefmenoxime into Cerebrospinal Fluid: A Comparative Study
between the Intravenous Bolus Injection and Intravenous Drip Infusion
   S. Kashiwagi et al. ................................................. 1063
Cefmenoxime – Pharmacokinetics in the Neonate
   J. Sarangues et al. .................................................. 1065
Pharmacokinetics of Cefmenoxime in Elderly Patients (60-90 Years Old)
with a Normal Renal Function after 1.0 g i.v. Bolus
   P. Veyssier et al. .................................................. 1067
Comparative Studies on Bactericidal Activity, β-Lactamase Susceptibility
and Other in vitro Characteristics of Ceftizoxime
   S. Selwyn and M. Bakhtiar ...................................... 1069
Bone Tissue Concentration of Ceftizoxime
   T. Makiyama and T. Asai ......................................... 1071
The Comparative Efficacy of Ceftizoxime and Cefotaxime in Severe Infections
   S. Segev et al. ...................................................... 1073
Activity of Cefmetazole Assessed by the Comparison of Timed Bacteriostatic
and Bactericidal Concentrations
   G. Masuda et al. .................................................... 1075
Activity of Cefmetazole in Comparison to Cefoxitin and Cephalothin in vitro
and in Treatment of Experimental Infections in Mice
   R. V. Goering et al. ................................................. 1077
Transference of Cefmetazole and Fosfomycin into Prostatic Tissues
   S. Ra et al. .......................................................... 1079
Clinical Study of Cefmetazole in Respiratory Tract Infections
   K. Nakagami et al. .................................................. 1081
A Clinical Study with Cefmetazole
   W. Holloway ........................................................ 1083
Clinical Evaluation of Cefmetazole Alone in the Treatment of Bacteremia
Not Responding to Other Antibiotics
   G.-Y. Liu et al. ........................................................ 1085
Clinical Evaluation of Cefmetazole in the Field of Urology
   I. Miyagawa et al. .................................................. 1087
Clinical Evaluation of Cefmetazole in Treatment of Complicated Urinary
Tract Infection
   T.-C. Tsai et al. .................................................... 1089
Clinical Evaluation of Cefmetazole in Obstetrics and Gynecology
   T. Chimura et al. ................................................... 1091
Clinical Results with Cefmetazole in Gynecological and Obstetrical Infections
and in Prophylactic Use after Surgery
   M. Ozaki et al. ...................................................... 1093
Clinical Evaluation of Cefmetazole for Prophylaxis in Patients Undergoing
Gynecological Surgery
   K. Fujiwara et al. ................................................... 1095
Cefotetan and Cefmetazole Concentrations in the Tissue of Patients at the Abdominal Operations
H. Furuhata et al. .................................................. 1097

Biliary Pharmacokinetics and Gallbladder Bile Concentration of Cefotetan in Healthy Volunteers
A. Lanzini et al. .................................................. 1099

Clinical Study on Penetration of Cefotetan into CSF
A. Hirayama et al. .................................................. 1101

Comparative Study of Cefotetan versus Cefoxitin in the Treatment of Acute Bacterial Infections
H. K. Horsch .................................................. 1103

A Comparison of the Efficacy and Safety of Cefotetan with That of Moxalactam in the Treatment of Hospitalized Patients with Acute Lower Respiratory Tract Infections
T. M. Nolen et al. .................................................. 1104

A Clinical Trial of Cefotetan in the Treatment of Severe Cervico-facial Infection of Dental Origin
A. A. Quayle et al. .................................................. 1107

Cefotetan in the Treatment of Anaerobic Infections: Clinical Efficacy and the Comparison of Clinical Outcome with in vitro Susceptibility of Anaerobes
J. C. H. Lee and A. L. Barry .................................................. 1109

Comparative Pharmacokinetic Studies of Cefotetan and Other Cephamycin Antibiotics: Cefminox, Cefbuperazone, Cefmetazole, Cefoxitin, and Latamoxef
Y. Akieda et al. .................................................. 1111

Pharmacokinetics of Patients with Serious Sepsis
S. D. Scott et al. .................................................. 1113

Prophylactic Use of Cefotetan: A Long Acting Cephamycin for the Patients under Abdominal Surgery
M. Murata et al. .................................................. 1115

The Use of Cefotetan in Surgical Prophylaxis
B. Mason et al. .................................................. 1117

Peritonitis, Septicaemia and Serious Intra-abdominal Infections: Research Experience with Cefotetan in a Surgical Controlled Clinical Trial
S. D. Scott et al. .................................................. 1119

Cefotetan Concentration in Non-traumatic Joint Effusion
M. Bonadio et al. .................................................. 1121

Clinical Evaluation of Cefotetan in Renourinary and Extraurinary Infections
G. F. Abbate et al. .................................................. 1123

In vitro Activity, Pharmacokinetics, Safety and Therapeutic Efficacy of Cefotetan in Patients with Complicated Urinary Tract Infections
K. G. Naber et al. .................................................. 1125

Cefotetan versus Moxalactam in the Treatment of Acute Bacterial Lower Respiratory Tract Infections
T. M. File et al. .................................................. 1127

Clinical and Laboratory Studies of Cefbuperazone, a Long Acting Cephamycin, in a Suburban Community Hospital
T. Madhaven and D. Cunningham .................................................. 1129

Improved Outer Membrane Permeabilities of 6315-S and 2355-S in Escherichia coli
Y. Komatsu et al. .................................................. 1131
## CONTENTS

Moxalactam in the Treatment of Nosocomial Infections: Clinical Experience
P. Nikolaidis et al. .......................................................... 1133

Chemistry and *in vivo* Activities of New Oral Prodrugs of a Potent
Aminothiazoloximino Cephalosporin
W. V. Curran et al. .......................................................... 1135

 Antibiotic Activity of CL 118,673, a New Oral Cephalosporin
N. A. Kuck et al. .......................................................... 1137

 Chemotherapeutic Efficacy and Pharmacokinetics of CGP 19 359,
a New Oral Cephalosporin, in Experimental Animals
O. Zak et al. .......................................................... 1139

 Pharmacokinetics of CGP 19 359, a New Oral Cephalosporin
W. Tosch et al. .......................................................... 1141

 Antibacterial Activities of FK 089, a New Oral Cephalosporin
T. Takaya et al. .......................................................... 1143

 Pharmacokinetics of FK 089, a New Oral Cephalosporin, in Animals
Y. Mine et al. .......................................................... 1145

 Pharmacokinetics and Safety of FK 089 in Healthy Volunteers
T. Suematsu et al. .......................................................... 1147

 BMY 28100, a New Oral Cephalosporin: Synthesis and Structure-activity
 Relationships
T. Naito et al. .......................................................... 1149

 Preliminary Laboratory Evaluation of BMY 28100
K. Tomatsu et al. .......................................................... 1151

 BMY 28100, a New Oral Cephalosporin: Activity *in vitro*
F. Leitner et al. .......................................................... 1153

 BMY 28100: Therapeutic Efficacy and Pharmacokinetics in Rodents
Y. H. Tsai et al. .......................................................... 1155

 Clinical Studies of FK027, a New Oral Cephalosporin, in Respiratory Tract
Infections, and Its Pharmacokinetics
K. Konishi and M. Tamura .......................................................... 1157

 Treatment of Cholangitis Using New Orally Active Cephalosporin FK027:
Its Basic Studies and Clinical Application
T. Shimizu et al. .......................................................... 1159

 Experimental and Clinical Evaluation of FK027 Activity in the Treatment
of Urinary Tract Infections
H. Kishi et al. .......................................................... 1161

 Clinical Usefulness of FK027, a New Oral Cephalosporin, in the Treatment
of Urinary Tract Infections
K. Suzuki et al. .......................................................... 1163

 Clinical Evaluation of FK027 on Urinary Tract Infections
Y. Ohi et al. .......................................................... 1165

 Serum and Sputum Concentration and Clinical Results of FK027 on Respiratory
Tract Infection
I. Hayashi .......................................................... 1167

 The *in vitro* and *in vivo* Antibacterial Activities of FK027, a New Orally Active
Cephalosporin
Y. Obana et al. .......................................................... 1169

 Clinical and Experimental Study of FK027 for Otorhinolaryngological Infection
Y. Fujimaki et al. .......................................................... 1171
CONTENTS

Fundamental and Clinical Studies of FK027, a New Oral Cephalosporin
M. Yamamoto et al. .......................................................... 1173

Clinical Study of FK027 in the Treatment of Respiratory Tract Infection
N. Aoki et al. ................................................................. 1175

Antibacterial Activities of Ro 15-8074, a New Oral Cephalosporin
W. W. S. Ng et al. .......................................................... 1177

T-2588, a Third-generation Oral Cephalosporin: Human Pharmacokinetics
J. Shimada et al. ............................................................ 1179

Clinical Study of a New Oral Antibiotic, T-2588 of the Cephems, in the Field
of Internal Medicine
R. Soejima et al. ............................................................ 1181

Treatment of Urinary Tract Infections with T-2588, a New Oral Cephalosporin
Y. Kawada and T. Nishiura ............................................. 1183

Cefuroxime-axetil versus Augmentin: Pharmacokinetics and Fecal Flora
after Multiple Doses over 8 Days
H. Langmaack et al. .......................................................... 1185

§7. Penem and Penam Antibiotics

In vitro Antibacterial Activity of MK 0787 (N-Formimidoylthienamycin), Aztreonam,
Sultamicillin, Ceftazidime against Pseudomonas pseudomallei (Meliodosis)
and Other Clinical Isolates
D. Tanphaichitra and S. Srimuang .................................... 1189

The Superiority of Imipenem over Currently Available Anti-pseudomonal Antibiotics
among Community Hospital Clinical Pathogens of Resistant Pseudomonas aeruginosa
T. Madhavan and B. Fitzsimons ......................................... 1191

β-Lactamase Induction in Pseudomonas aeruginosa by Imipenem and
Its Influence on Susceptibility Tests
D. M. Livermore ............................................................ 1193

Penetration of Primaxin (N-Formimidoylthienamycin and Cilastatin)
into Human Cerebrospinal Fluid
D. H. Dealy et al. ........................................................... 1195

Penetration of Imipenem and Cilastatin into Cerebrospinal Fluid of Patients
with Bacterial Meningitis
J. Modai et al. ............................................................... 1197

Clinical and Microbiological Results of Treatment with Imipenem/Cilastatin
U. Hartenauer et al. ......................................................... 1199

Evaluation of Imipenem/Cilastatin in the Treatment of Severe Infections
in Non-neutropenic Adult Patients
J. Garau et al. ............................................................... 1201

Comparative Efficacy of Imipenem (MK 787) Administered or in Combination
with Cilastatin, a Dehydropeptidase Inhibitor (MK 791), in the Treatment
of Complicated Urinary Tract Infections
J. F. Acar et al. ............................................................. 1203

Imipenem (Thienamycin) Therapy of Perforated and Gangrenous Appendicitis
P. N. R. Heseltine et al. ..................................................... 1205

Bile and Tissue Concentrations and Clinical Efficacy of MK-0787/MK-0791
in Surgical Infections
H. Tanimura et al. .......................................................... 1207
Effect of Imipenem Prophylaxis on Colon Microflora in Patients Undergoing Colorectal Surgery
L. Kager et al. ................................................................. 1209

Cilastatin-sensitive Lactamase Active on Carbapenem and Penem Antibiotics in the Lung of Rodents
R. Hajdu et al. ................................................................. 1211

Determination of Serum and Tissue Levels of Imipenem by HPLC
M. Erttmann et al. ............................................................ 1213

A Multiple Dose Pharmacokinetic and Treatment Study of Imipenem-Cilastatin in Patients with End-stage Renal Disease Undergoing Chronic Hemodialysis
S. Berman ................................................................. 1215

Serum and Lung Tissue Concentrations of Imipenem
K. Unertl et al. ................................................................. 1216

Clinical Experience with Imipenem/Cilastatin in the Following of Surgical Treatment
P. Kempf et al. ................................................................. 1218

An Open Study on the Efficacy, Safety and Tolerance of an i.v. Administered Imipenem/Cilastatin b.i.d. Regimen (2 x 1 g) in the Treatment of Hospitalized Patients
M. Wenzel et al. ................................................................. 1220

Imipenem/Cilastatin Treatment of Multiresistant Pseudomonas aeruginosa Lung Infection in Cystic Fibrosis
S. S. Pedersen et al. .......................................................... 1223

Imipenem in the Treatment of Septicemia
S. Breyer et al. ................................................................. 1224

Comparative in vitro Activity of SCH 34343 with 14 Antibiotics against 100 Gram-negative Blood Isolates
H. Giamarellou et al. .......................................................... 1226

The in vitro Antibacterial Activity of SCH 34343 Compared with That of Other β-Lactams
I. Phillips et al. ................................................................. 1228

Pharmacokinetics of SCH 34343 in Man
C. Lin et al. ................................................................. 1230

Comparison of the Efficacy and Safety of SCH 34343-Na with That of Cefamandole in the Treatment of Acute Lower Respiratory Tract Infection
L. A. Cone et al. ................................................................. 1232

A Comparison of the Efficacy and Safety of SCH 34343 and Cefamandole in the Treatment of Acute Respiratory Tract Infections
T. M. Nolen et al. ................................................................. 1234

Comparison of SCH 34343 with Cefotaxime in the Treatment of Difficult Urinary Tract Infections
C. E. Cox and D. L. Santomauro ........................................... 1236

Comparison of SCH 34343 with Cefoxitin in the Treatment of Skin and Skin Structure Infections
R. L. Nichols et al. ................................................................. 1238

Penem Antibiotic FCE 22891: Tissue and Body Fluid Distribution in Mice and Therapy of Experimental Diseases
D. Jabes et al. ................................................................. 1240

Activity of FCE 22101 on Gram-negative Bacteria Resistant to 3rd Generation Cephalosporins
C. Della Bruna and A. Sanfilippo ........................................... 1242
Activity of the Penem FCE 22101 on Gram-negative Bacteria Induced for β-Lactamase
A. Sanfilippo et al. 1244

Susceptibility of Clinical Isolates to Temocillin, a Recently Introduced Penicillin
with Narrow Antimicrobial Spectrum
H. D. Heilmann and K. Kühn 1246

Clinical Evaluation of Temocillin in Serious Infections
P. D. Welsby et al. 1248

Temocillin Therapy of Patients with Hepatobiliary Infections
D. Tanphaichitra et al. 1250

The Activity of Temocillin, Amoxicillin/Clavulanic Acid and Ticarcillin/
Clavulanic Acid: An Epidemiological Multicenter Survey in Eight Hospitals
G. Th. J. Fabius et al. 1252

Clinical Results and Pharmacokinetics of Temocillin in Surgical Patients
H. E. Klein et al. 1254

The Treatment of Gram-negative Infection with Temocillin 1g 12-hourly
G. Lindsay et al. 1256

Miraxid® (Pivampicillin/Pivmecillinam) Evaluated: Four Clinical Studies
Involving 794 Patients
E. C. Moorhouse et al. 1258

Therapy of Uncomplicated Gonococcal Urethritis with VD 2085
D. Tanphaichitra and O. Christensen 1260

In vitro Synergistic Activity of Sulbactam and Cefoperazone against Aerobic Bacteria
D. N. Wright et al. 1262

Sulbactam-Ampicillin versus Moxalactam as an Adjunct to Surgery
in Acute Cholecystitis: A Preliminary Report
A. E. Yellin et al. 1264

Comparative Clinical Study of Sulbactam/Ampicillin and Clindamycin/Tobramycin
in Polymicrobial Infections
B. V. Stromberg et al. 1266

In vivo and in vitro Comparison of YTR 830 and Clavulanate Combined
with Amoxicillin against Staphylococcus aureus
S. Aronoff et al. 1268

In vivo Comparison of YTR 830 and Clavulanate Combined
with Amoxicillin against Citrobacter freundii and Proteus mirabilis
S. Aronoff et al. 1270

Inhibition of β-Lactamases, Binding to PBPs and Morphological
Changes Affected by YTR 830, a New Penicillinate Sulphone
F. Moosdeen et al. 1272

YTR 830, a Novel β-Lactamase Inhibitor: Comparative in vitro and in vivo Studies
with Clavulanic Acid and Sulbactam
N. Ishida et al. 1274

Evaluation of New β-Lactamase Inhibitor YTR 830
M. D. Kitzis et al. 1276

Comparison of YTR 830, Sodium Clavulanate and Sulbactam Combined
with Broad-spectrum Penicillins against β-Lactamase-producing Enterobacteriaceae
and Pseudomonas
M. R. Jacobs et al. 1278

Mutual Prodrugs of Ampicillin and 6β-Halopenicillanic Acids
W. von Daehne et al. 1280
The Penetration of Amoxicillin and Clavulanic Acid into the Cerebrospinal Fluid of Patients with Inflamed Meninges
J. S. Bakken et al. ........................................ 1282
Clinical Evaluation of Augmentin Therapy in Anaerobic Infection of Skin and Soft Tissues
S. Balasubramaniam et al. ................................ 1284
Comparative in vitro Activity of Amoxicillin/Potassium Clavulanate and Imipenem/Cilastatin against Anaerobic Bacteria Isolated from Community Hospitals
E. J. C. Goldstein and D. M. Citron .......................... 1286
Resistance to β-Lactam Antibiotics and to Combinations of Amoxicillin/Clavulanic Acid (Augmentin) and Ticarcillin/Clavulanic Acid (Timentin): Distribution of Phenotypes in Enterobacteriaceae
D. Sirot et al. .................................................. 1288
Pharmacokinetics of Augmentin and Timentin in Ear- and Eye-Fluids and in Serum
P. J. Federspil et al. ........................................... 1290
Pharmacokinetic Studies on Clavulanate Potentiated Ticarcillin (Timentin) in Normal Subjects and Patients with Renal Insufficiency
P. Koeppe et al. ................................................ 1293
Timentin: Pharmacokinetics and Clinical Results in Surgical Patients
R. R. Wittke and D. Adam ..................................... 1295
Comparison of Ticarcillin-Clavulanic Acid Combination with Cefazolin in the Treatment of Soft Tissue Infections
H. Katner et al. ................................................ 1297
Timentin (BRL-28500) in the Treatment of Complicated Adult Urinary Tract Infections
R. Gebhart et al. .............................................. 1299
Timentin: In vitro Efficacy against 712 Isolates of Aerobic-anaerobic Bacteria
M. B. Bansal et al. ............................................ 1301
Comparative Evaluation of the in vitro Activity of Ticarcillin and Ticarcillin-Clavulanic Acid in Hospital Practice
V. Jarlier et al. ................................................. 1303
Antibacterial Activity of Timentin according to Patterns of Susceptibility to β-Lactam Antibiotics and Strain Origin
T. Fosse et al. .................................................. 1305
In vitro Bactericidal Activity of Clavulanate/Ticarcillin Combinations
I. M. Gould et al. ............................................. 1308
Pharmacokinetics of Antibiotics Combined with β-Lactamase Inhibitors in Patients with Renal and/or Hepatic Dysfunctions
Y. Usuda et al. ............................................... 1310
In vitro and Clinical Evaluation of Intravenous Timentin in Soft Tissue Infections
B. Rao et al. .................................................. 1312
The Use of Timentin in the Treatment of Moderate and Severe Infections
J. D. Price et al. ............................................. 1314
A Randomized Study Comparing Timentin with Piperacillin and Tobramycin Treatment of Septicemia and Lower Respiratory Infections
D. Winslow and W. Holloway .............................. 1316
Timentin: Clinical Experiences in German Hospitals
J. Johnsen et al. ............................................. 1318
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timentin Compared to Tobramycin-Piperacillin Combination as Empiric Therapy in Serious Infections in Hospitalized Patients</td>
<td>T. Madhavan et al.</td>
<td>1320</td>
</tr>
<tr>
<td>The Use of Clavulanate Potentiated Ticarcillin in Neonatal Sepsis</td>
<td>M. F. Smith et al.</td>
<td>1323</td>
</tr>
<tr>
<td>BRL 28500 (Ticarcillin + Clavulanic Acid) in the Pre- and Peri-operative Treatment of Complicated Urinary Tract Infection</td>
<td>M. Westenfelder et al.</td>
<td>1325</td>
</tr>
<tr>
<td>Ticarcillin/Clavulanic Acid Treatment of Gynecological Infections with Special Reference to the Blood and Tissue Concentrations</td>
<td>K. Gutschow et al.</td>
<td>1327</td>
</tr>
</tbody>
</table>

§8. Monobactams

Pharmacokinetics of Carumonam in Patients with Renal Insufficiency | K. Stoeckel et al. | 1331 |
Kidney Tolerance of Monobactam (Ro 17-2301), Flucloxacillin and the Combination of Both Using Parameters for Proximal and Distal Tubular Injury | A. W. Mondorf et al. | 1333 |
Single Dose Pharmacokinetics and Absolute Bioavailability of the New Monocyclic β-Lactam Carumonam (Ro 17-2301, AMA-1080) | E. Weidekamm et al. | 1335 |
In vitro Activity of the Monobactam Ro 17-2301 Compared with Aztreonam and Other β-Lactam Antibiotics | D. A. Bremner | 1337 |
An E. coli Strain Which Developed Resistance to Aztreonam But Not to Carumonam (Ro 17-2301): Resistance Development Kinetics and β-Lactamase | M. Arisawa et al. | 1339 |
In vitro Activity of Ro 15-8074, SQ 82291 and Ro 17-2301 vs Other β-Lactams against 300 Recent Nosocomial Pathogens | K. Kanellakopoulou et al. | 1341 |
Comparative in vitro Evaluation of Ro 17-2301, a New Monobactam Antibiotic | J. LeFrock et al. | 1343 |
Comparative Activity of Ro 17-2301, HR 810, Ceftazidime and Aztreonam for Resistant Pseudomonas aeruginosa | S. M. Smith and R. H. K. Eng | 1345 |
In vitro Evaluation of Ro 17-2301, a New Monobactam Antibiotic | E. E. Stobberingh et al. | 1347 |
The in vitro Activity of Ro 17-2301 against Pseudomonas Clinical Isolates in Comparison to Aminoglycosides and Aztreonam | A. Georgopoulos et al. | 1349 |
In vitro and Clinical Evaluation of Ro 17-2301, a New N-Sulfo β-Lactam Antibiotic, in Severe Urinary Tract Infections | C. A. Barclay et al. | 1351 |
Oral Monobactams: Comparative in vitro Activity of SQ 82,291 and Other Antimicrobial Agents | A. G. Paradelis et al. | 1355 |
<table>
<thead>
<tr>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penetration of Aztreonam into Tissues and Fluids of the Female Genital</td>
<td>1359</td>
</tr>
<tr>
<td>Tract in Patients Undergoing Surgery</td>
<td></td>
</tr>
<tr>
<td>D. Vernant et al.</td>
<td></td>
</tr>
<tr>
<td>Concentrations of Aztreonam in Serum, Muscle, Fat and Renal Tissue</td>
<td>1361</td>
</tr>
<tr>
<td>M. Westenfelder et al.</td>
<td></td>
</tr>
<tr>
<td>Monobactam Metabolism in Patients with Biliary Tract Infection Related</td>
<td>1363</td>
</tr>
<tr>
<td>with Its Fundamental and Clinical Study</td>
<td></td>
</tr>
<tr>
<td>T. Saito et al.</td>
<td></td>
</tr>
<tr>
<td>In vitro and in vivo Effects of Aztreonam and Placebo on Platelet Function and Bleeding Time in Normal Volunteers</td>
<td>1365</td>
</tr>
<tr>
<td>T. A. Tartaglione et al.</td>
<td></td>
</tr>
<tr>
<td>Aztreonam, an Alternative β-Lactam in Patients with Hypersensitivity to Penicillins and Cephalosporins</td>
<td>1367</td>
</tr>
<tr>
<td>W. Graninger et al.</td>
<td></td>
</tr>
<tr>
<td>Clinical Experience with Aztreonam</td>
<td>1369</td>
</tr>
<tr>
<td>J. Righter et al.</td>
<td></td>
</tr>
<tr>
<td>Treatment of Gram-negative Septicaemia with Aztreonam</td>
<td>1371</td>
</tr>
<tr>
<td>S. Lauwers et al.</td>
<td></td>
</tr>
<tr>
<td>Therapeutic Effect of Aztreonam for Severe Infections Associated with Hematological Disorders</td>
<td>1373</td>
</tr>
<tr>
<td>T. Masaoka et al.</td>
<td></td>
</tr>
<tr>
<td>Evaluation of Aztreonam in an Implantable Drug Pump for the Treatment of Gram-negative Osteomyelitis</td>
<td>1375</td>
</tr>
<tr>
<td>C. R. Perry et al.</td>
<td></td>
</tr>
<tr>
<td>Treatment of Acute Pelvic Inflammatory Disease with Aztreonam Plus Clindamycin</td>
<td>1377</td>
</tr>
<tr>
<td>M. G. Dodson et al.</td>
<td></td>
</tr>
<tr>
<td>Multicentre Comparative Study between Aztreonam (o.d.) and Gentamicin (b.i.d.) in Renal and Urinary Tract Infections Treatment</td>
<td>1379</td>
</tr>
<tr>
<td>A. Albertazzi et al.</td>
<td></td>
</tr>
<tr>
<td>Experience with Some New Antibiotics in Urinary Tract Infections</td>
<td>1381</td>
</tr>
<tr>
<td>M. S. Sabbour et al.</td>
<td></td>
</tr>
<tr>
<td>Well-controlled Comparative Study on Aztreonam and Cefoperazone in the Treatment of Complicated Urinary Tract Infections</td>
<td>1383</td>
</tr>
<tr>
<td>H. Ohmori et al.</td>
<td></td>
</tr>
<tr>
<td>Randomized Comparison of the Efficacy and Safety of Aztreonam vs. Cefuroxime in the Treatment of Serious Gram-negative Urinary Tract Infections and Serum Pharmacokinetics of Aztreonam in Patients</td>
<td>1385</td>
</tr>
<tr>
<td>G. Friman et al.</td>
<td></td>
</tr>
<tr>
<td>Aztreonam: European Experience in the Treatment of Pediatric Patients with Gram-negative Infections</td>
<td>1387</td>
</tr>
<tr>
<td>D. Adam</td>
<td></td>
</tr>
<tr>
<td>Efficacy of Aztreonam in the Treatment of Gram-negative Rod Bacteremia and Meningitis</td>
<td>1390</td>
</tr>
<tr>
<td>P. McKellar</td>
<td></td>
</tr>
<tr>
<td>Studies of Aztreonam in Cancer Patients</td>
<td>1392</td>
</tr>
<tr>
<td>G. Bodey et al.</td>
<td></td>
</tr>
<tr>
<td>Sensitivity to Aztreonam in 2613 Strains of Enterobacteriaceae</td>
<td>1394</td>
</tr>
<tr>
<td>at a Norwegian County Hospital</td>
<td></td>
</tr>
<tr>
<td>E. Holten</td>
<td></td>
</tr>
</tbody>
</table>
The β-Lactamase Stability and *in vitro* Activity of Aztreonam, with a Comparison to 9 Other β-Lactam Antibiotics and Gentamicin

H. Friis *et al.* ................................................................. 1396

Clinical Evaluation of Aztreonam in Severe Urinary Tract Infections

P. J. Van Cangh *et al.* ...................................................... 1398

Aztreonam in the Therapy of Nosocomial Infections in High Risk Patients

P. Cristiano *et al.* ............................................................. 1400

§9. Macrolide Antibiotics

*In vitro* Susceptibility of Streptococci and Staphylococci from Clinical Material to a Novel Macrolide: RU 28965

E. Debbia *et al.* .......................................................... 1405

*In vitro* Activity of RU 28965 Evaluated by the Agar Dilution Methods and MS-2-research System

P. Periti and P. Nicoletti ............................................. 1407

*In vitro* Activity of RU 28965, a New Macrolide, in Comparison with Erythromycin and Ampicillin against *Haemophilus* spp.

G. Nicoletti *et al.* ........................................................ 1409

*In vitro* Activity of RU 28965, a New Macrolide, against *Chlamydia trachomatis* and *Ureaplasma urealyticum*

R. Cevenini *et al.* ....................................................... 1411

*In vitro* Effect of RU 28965 and Other Macrolide Antibiotics on Human Neutrophil Functions

A. Fietta *et al.* ........................................................... 1413

Synergy between RU 28965 and Human Neutrophils on Bactericidal Activity *in vitro*

M. T. Labro *et al.* ........................................................ 1415

Pharmacokinetic Properties of the New Macrolide RU 28965 in Animals

J. F. Chantot and A. Bryskier ........................................ 1417

*In vitro* Susceptibility of *Ureaplasma urealyticum* to RU 28965 Compared to Erythromycin and Josamycin

C. Bébéar *et al.* .......................................................... 1419

Influence of Food on the Absorption of RU 965, a New Macrolide Antibiotic, from Film-coated Tablets in Healthy Men

H. B. Lassman *et al.* .................................................... 1421

Safety, Tolerance, and Pharmacokinetics of Single and Multiple Oral Doses of RU 965, a New Macrolide Antibiotic, in Healthy Men

S. K. Puri *et al.* ........................................................... 1423

Bacteriological Evaluation of a New Macrolide Antibiotic, Rokitamycin (TMS-19-Q)

T. Morohoshi *et al.* ..................................................... 1425

Metabolism of Rokitamycin (TMS-19-Q), a New 16-Membered Macrolide Antibiotic, and Effects of Its Metabolites on Plasma Level as Total Activity

T. Suzuki *et al.* ........................................................... 1427

Formulation Design of Rokitamycin (TMS-19-Q) Tablet and Its Evaluation

M. Morishita *et al.* ........................................................ 1429

Clinical Effect of Rokitamycin (TMS-19-Q): Comparison of Different Formulations

K. Hara *et al.* .............................................................. 1431

*In vitro* Anti-mycoplasmal Activity of Miocamycin: MIC and Sub-MIC Study

P. M. Furneri *et al.* ....................................................... 1433
In vitro Antibacterial Activity of Miocamycin
A. Yoshida et al. ........................................ 1435
The Activity of Miocamycin against Chlamydia trachomatis and Mycoplasmas in vitro
G. L. Ridgway et al. .................................... 1437
Anti-staphylococcal Activity of Miocamycin
A. Repetto et al. ........................................ 1439
Effects of Miocamycin on Bacterial Surface and Its Relationship with Adherence
P. Mastroeni et al. ...................................... 1441
Miocamycin versus Professional Phagocytic Cells
L. Bonina et al. .......................................... 1444
Plasma and Tissue Concentrations of Miocamycin in Humans
F. Fraschini et al. ....................................... 1447
Absorption and Excretion of Miocamycin Tablets and Dry Syrup
K. Fukaya et al. .......................................... 1450
Single and Multiple Dose Pharmacokinetics and Tolerance of Miocamycin in Healthy European Volunteers
S. W. Sanders et al. ...................................... 1452
Miocamycin for the Management of Respiratory Tract Infections
R. Rimoldi et al. .......................................... 1454
Efficacy and Tolerability of Miocamycin: A New Macrolide in Pediatrics
O. Olivi .................................................... 1457
Results Obtained with Miocamycin in the Treatment of Pyodermas in Children
I. Obadia .................................................. 1461
Clinical Effect of Miocamycin on Whooping Cough
Y. Sakata et al. ........................................... 1463
Miocamycin in the Therapy of Pertussis, Scarlet Fever and Mycoplasma pneumoniae Infections in Children
A. Ulivelli et al. .......................................... 1465
Usefulness of Miocamycin in the Treatment of Surgical Infections
R. Germiniani ............................................. 1467
Miocamycin Treatment of Otorhinolaryngological Infections
G. Catalano et al. ........................................ 1470
Susceptibility of Clinical Isolates to Josamycin, Erythromycin and Penicillin
A. Wildfeuer et al. ....................................... 1473
Effect of Josamycin on the Phagocytic and Microbicidal Function of Leukocytes
G. Privitera et al. ........................................ 1476
Activity of Josamycin in Human Tissue and Neutrophils
A. Wildfeuer et al. ....................................... 1478
Influence of Josamycin on Caffeine Disposition in Human Healthy Volunteers
J. Descotes et al. ......................................... 1481
Effects of Food on Bioavailability of Josamycin and Josamycin Propionate
C. Ikeda et al. ............................................. 1483
Clinical Studies with Josamycin in Adults and Children
A. J. Moritz ................................................ 1485
Rational Basis of Antibiotic Therapy in Acute Pulmonary Infections in Children
M. Solbiati et al. ......................................... 1488
Mycoplasma pneumoniae Pneumonia: Clinical Aspects and Therapeutical Problems
F. De Rosa et al. .......................................... 1490
Clinical Experience with Josamycin in the Therapy of *Mycoplasma pneumoniae* Pneumonia

H. Kobayashi .................................................. 1492

*In vitro* Studies and Clinical Effect of Josamycin in *Mycoplasma pneumoniae* Pneumonia

S. Ogawa et al. ................................................. 1494

Clinical Evaluation of Josamycin Treatment in Mycoplasmal pneumonia in Children

T. Fujimoto et al. ............................................. 1496

Josamycin in the Treatment of Papulo Pustular Acne

E. Rampini et al. ............................................. 1498

Prophylactic Josamycin for Traveller's Diarrhoea

J. P. Ghanassia et al. ........................................ 1500

Josamycin and Host Defense

A. Wildfeuer .................................................. 1502

Efficacy of Josamycin in the Treatment of Infections of the Respiratory and Ear, Nose and Throat Tracts

B. Wassmer et al. ............................................. 1505

Spiramycin Half-life within Macrophages, Spleen, Thymus, and Liver Tissues *in vivo*

S. Kernbaum et al. ............................................ 1507

*In vivo* Effects of Spiramycin on Non-specific and Specific Immunity

M. Levacher et al. ............................................ 1509

Susceptibility of Anaerobic Bacteria to Eight Macrolides and Related Drugs

C. Quentin et al. ............................................. 1511

§10. Quinolone Antibacterials

*In vitro* Antibacterial Activity of AT-3295, a New Pyridonecarboxylic Acid Derivative

S. Nakamura et al. ............................................ 1515

*In vivo* Effect of AT-3295 against Experimental Infections

A. Minami et al. ............................................. 1517

AT-3295, a New Pyridonecarboxylic Acid Derivative with Potent Antibacterial Activity: Synthesis and Structure-activity Relationships

J. Matsumoto et al. ........................................... 1519

*In vitro* Evaluation of Two New 4-Quinolones: S25930 and S25932

D. Felmingham et al. ......................................... 1521

Resistance Studies with Two New 4-Quinolones: S25930 and S25932

D. Felmingham et al. ......................................... 1523

CI-934: A New Antistreptococcal Quinolone – *In vitro* and Chemotherapeutic Studies

E. L. Marcus and C. L. Heifftz ............................... 1525

Evaluation of the Activity of A-56619 and A-56620, Two Novel Quinolone Antimicrobial Agents, on Aerobic Microorganisms

B. Gordts et al. ............................................... 1527

*In vitro* Evaluation of Two Quinolones, A-56619 and A-56620

A. L. Barry et al. ............................................ 1529

Spectrum and Antibacterial Activity of Abbott A-56619 and A-56620 in Comparison to Other Quinolones

P. M. Shah et al. ............................................. 1531

*In vitro* Activity of A-56619 and A-56620 Compared to Ciprofloxacin, Norfloxacin, and Vancomycin

S. G. Kelley et al. ........................................... 1533
<table>
<thead>
<tr>
<th>Title</th>
<th>Authors</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>In vitro Antibacterial Activity of Aryl-fluoro Quinolones A-56619 and A-56620 against Routine and Multi-resistant Clinical Isolates</td>
<td>V. Ackerman et al.</td>
<td>1535</td>
</tr>
<tr>
<td>Comparative in vitro and in vivo Potencies of A-56619, Ofloxacin, and Ciprofloxacin</td>
<td>P. B. Fernandes et al.</td>
<td>1537</td>
</tr>
<tr>
<td>Comparative in vitro and in vivo Potencies of A-56620, Ofloxacin, and Ciprofloxacin</td>
<td>D. Chu et al.</td>
<td>1539</td>
</tr>
<tr>
<td>Treatment of Experimental Pneumonia due to <em>Pseudomonas aeruginosa</em> in Neutropenic Guinea Pigs with a Quinolone (Abbott-56619)</td>
<td>J. Kapusnik et al.</td>
<td>1541</td>
</tr>
<tr>
<td>In vitro and in vivo Activity of Ciprofloxacin (BAY o9867): A New Quinoline Derivative, Alone and in Combination against Various <em>E.coli</em>, <em>Mycobacterium</em> and <em>Salmonella</em> Strains</td>
<td>M. Rosenfeld and J. K. Seydel</td>
<td>1543</td>
</tr>
<tr>
<td>Ultrastructure and Reversion of Bacterial Filaments Produced with Ciprofloxacin</td>
<td>V. Lorian et al.</td>
<td>1545</td>
</tr>
<tr>
<td>Influence of Media and Method on the in vitro Susceptibility of <em>Pseudomonas aeruginosa</em> and Other Bacteria to Ciprofloxacin and Enoxacin</td>
<td>J. Blaser et al.</td>
<td>1547</td>
</tr>
<tr>
<td>In vivo Efficacy of Ciprofloxacin Compared with Cefbuperazone, Cefoperazone and Cefoxitin in the Treatment of Experimental Intra-abdominal Abscess</td>
<td>M. B. Bansal et al.</td>
<td>1549</td>
</tr>
<tr>
<td>Comparative Efficacy of Ciprofloxacin, Azlocillin and Tobramycin Alone and in Combination in Experimental <em>Pseudomonas</em> Sepsis</td>
<td>M. Johnson et al.</td>
<td>1551</td>
</tr>
<tr>
<td>Comparison of the Efficacy of Ciprofloxacin, BMY 28142 and Ceftazidime in the Therapy of Experimental <em>Pseudomonas aeruginosa</em> Endocarditis in the Rat: Importance of the Dosing Interval</td>
<td>M. J. Ingerman et al.</td>
<td>1553</td>
</tr>
<tr>
<td>Ciprofloxacin Alone and Combined with Azlocillin, Ceftizoxime, and Amikacin, against Gram-negative Bacilli in a Neutropenic Site Model</td>
<td>L. R. Peterson et al.</td>
<td>1555</td>
</tr>
<tr>
<td>Bactericidal Activity of Ciprofloxacin against Amikacin-resistant Gram-negative Bacilli and Methicillin-resistant <em>Staphylococcus aureus</em></td>
<td>M. S. Simberkoff and J. J. Rahal, Jr.</td>
<td>1557</td>
</tr>
<tr>
<td>Comparative Activity of Ciprofloxacin (BAY o9867) with β-Lactam Antibiotics and Gentamicin, and the Effect of Inoculum Size, against Aerobic Gram-positive and -negative Bacteria</td>
<td>K. E. Aldridge et al.</td>
<td>1559</td>
</tr>
<tr>
<td>Evaluation of Ciprofloxacin and Cefotaxime in the Treatment of Experimental Subcutaneous Abscess in Mice Due to Aerobes</td>
<td>H. Thadepalli et al.</td>
<td>1561</td>
</tr>
<tr>
<td>The Effect of Ciprofloxacin on the Viability and Morphology of Methicillin-resistant <em>Staphylococcus aureus</em></td>
<td>S. M. Smith et al.</td>
<td>1563</td>
</tr>
<tr>
<td>Comparative in vitro Activity of Ciprofloxacin</td>
<td>A. Fernández et al.</td>
<td>1565</td>
</tr>
<tr>
<td>In vitro Activity of Ciprofloxacin against Multi-resistant Staphylococci and Gram-negative Rods</td>
<td>C. Fernandes et al.</td>
<td>1567</td>
</tr>
</tbody>
</table>
In vitro Activity of Ciprofloxacin (BAY o9867) and Three Other Antibiotics against Multiresistant Strains of Pseudomonas
G. S. R. Davies and J. Cohen ........................................ 1569

Antibacterial Activity of 19 Antimicrobial Agents and Kill Kinetics of Ciprofloxacin Plus Ampicillin against Gentamicin-resistant and High-level-resistant Enterococci
H. Grimm ................................................................. 1571

The Effects of Oral Ciprofloxacin on the Faecal Flora of Healthy Volunteers
H. A. Holt et al. .......................................................... 1573

Pharmacokinetics of Ciprofloxacin in Healthy Volunteers after Oral and Intravenous Administration
K. Borner et al. ............................................................ 1575

Ciprofloxacin Pharmacokinetics in Renal Failure
E. Singlas et al. ......................................................... 1577

Penetration of Ciprofloxacin into Bone Tissues
R. Braun et al. .......................................................... 1579

Ciprofloxacin Concentrations in Tonsils Following Single and Repeated Administration
N. Falser et al. ............................................................ 1581

Penetration of Ciprofloxacin into Nasal Secretions
U. Ullmann et al. ......................................................... 1583

Effect of the Gastric Emptying Time on Rate and Extent of the Systemic Availability of Ciprofloxacin (BAY o9867) in Humans
W. Wingender et al. ..................................................... 1585

A Clinical and Pharmacokinetic Study of Ciprofloxacin Administered Chronically as i.v. Bolus Doses to Young Healthy Volunteers
D. B. Jack et al. .......................................................... 1587

Biliary Elimination of Ciprofloxacin in Man: A Comparative HPLC and Microbiological Evaluation
J. M. Brogard et al. ...................................................... 1589

Excretion of Intravenous and Oral Ciprofloxacin in Biliary Disease
C. J. L. Strachan and B. T. Thom ..................................... 1591

A Study of Ciprofloxacin Kinetics in Various Body-fluid Compartments
G. Petrikkos et al. ...................................................... 1593

Penetration of Ciprofloxacin into Female Genital Tract Tissues
E. Goormans et al. ...................................................... 1595

Ciprofloxacin Concentrations in the Female Genital Tract Organs
S. Segev et al. ........................................................... 1597

Ciprofloxacin Pharmacokinetics in Patients Undergoing Gastrointestinal Surgery
S. H. Silverman et al. ................................................... 1599

Pharmacokinetics of Oral Ciprofloxacin, 100 mg Single Dose, in Volunteers and Elderly Patients
A. P. Ball et al. .......................................................... 1601

Multiple-dose Pharmacokinetics and Tissue Penetration of Ciprofloxacin, 500 mg t.i.d.
M. LeBel et al. .......................................................... 1603

Interactions on the Gastrointestinal Absorption of Ciprofloxacin
G. Höffken et al. ........................................................ 1606

Pharmacokinetic Properties of Ciprofloxacin in Intensive Care Patients with Acute Renal Failure (Preliminary Data)
M. Dirksen et al. ........................................................ 1608
<table>
<thead>
<tr>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diffusion of Ciprofloxacin in the Human Prostatic Tissue after Oral</td>
<td>1610</td>
</tr>
<tr>
<td>and Intravenous Administration</td>
<td></td>
</tr>
<tr>
<td>K. Schalkhäuser et al.</td>
<td></td>
</tr>
<tr>
<td>Tissue Distribution of Ciprofloxacin Following Oral and Intravenous</td>
<td>1612</td>
</tr>
<tr>
<td>Administration</td>
<td></td>
</tr>
<tr>
<td>H.-U. Eickenberg and A. Dalhoff</td>
<td></td>
</tr>
<tr>
<td>The Penetration of Ciprofloxacin after Single Oral Dose in Normal and</td>
<td>1614</td>
</tr>
<tr>
<td>Infected Bones</td>
<td></td>
</tr>
<tr>
<td>I. W. Fong et al.</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin Pharmacokinetics in Patients with Impaired Renal Function</td>
<td>1616</td>
</tr>
<tr>
<td>D. B. Webb et al.</td>
<td></td>
</tr>
<tr>
<td>Pharmacokinetics of Ciprofloxacin: Study of Its Distribution in the</td>
<td>1618</td>
</tr>
<tr>
<td>Respiratory Secretions</td>
<td></td>
</tr>
<tr>
<td>E. Bergogne-Berezin et al.</td>
<td></td>
</tr>
<tr>
<td>Penetration of Ciprofloxacin into Human Lung Tissue Following a Single</td>
<td>1620</td>
</tr>
<tr>
<td>Intravenous Administration</td>
<td></td>
</tr>
<tr>
<td>D. Schlenkhoff et al.</td>
<td></td>
</tr>
<tr>
<td>Single Dose Pharmacokinetics of Oral Ciprofloxacin in Patients with</td>
<td>1622</td>
</tr>
<tr>
<td>Cystic Fibrosis</td>
<td></td>
</tr>
<tr>
<td>J. Goldfarb et al.</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin in Acute Exacerbations of Chronic Bronchitis</td>
<td>1624</td>
</tr>
<tr>
<td>S. Klein et al.</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin in Purulent Exacerbations of Chronic Bronchitis:</td>
<td>1626</td>
</tr>
<tr>
<td>A Clinical, Microbiological and Pharmacokinetic Study</td>
<td></td>
</tr>
<tr>
<td>B. I. Davies et al.</td>
<td></td>
</tr>
<tr>
<td>Non-comparative Study of Ciprofloxacin in Respiratory Tract Infection</td>
<td>1628</td>
</tr>
<tr>
<td>S. Mehtar et al.</td>
<td></td>
</tr>
<tr>
<td>Evaluation of the Clinical Efficacy and Safety of Ciprofloxacin (BAY</td>
<td>1630</td>
</tr>
<tr>
<td>o9867) in the Treatment of Respiratory Tract Infections</td>
<td></td>
</tr>
<tr>
<td>D. A. Campbell and R. M. du Bois</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin in the Outpatient Treatment of Urinary Tract Infections</td>
<td>1632</td>
</tr>
<tr>
<td>S. J. Childs</td>
<td></td>
</tr>
<tr>
<td>In vivo Efficacy of Ciprofloxacin Compared with Trimethoprim and the</td>
<td>1634</td>
</tr>
<tr>
<td>Treatment of Urinary Tract Infection in Hospital</td>
<td></td>
</tr>
<tr>
<td>A. H. Williams and R. N. Grüneberg</td>
<td></td>
</tr>
<tr>
<td>Comparative Efficacy and Safety of Ciprofloxacin (Bay o9867) and Cotrimoxazole in the Treatment of Patients with Complicated Urinary Tract Infections</td>
<td>1636</td>
</tr>
<tr>
<td>J. Boerema et al.</td>
<td></td>
</tr>
<tr>
<td>Clinical Experience with Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections</td>
<td>1638</td>
</tr>
<tr>
<td>K. Schalkhäuser and A. Dalhoff</td>
<td></td>
</tr>
<tr>
<td>Ciprofloxacin in the Treatment of Patients with Symptomatic and</td>
<td>1640</td>
</tr>
<tr>
<td>Asymptomatic Urinary Tract Infections: A Comparative Study of Single-dose Application versus</td>
<td></td>
</tr>
<tr>
<td>Three-day Treatment Concerning Efficacy and Safety</td>
<td></td>
</tr>
<tr>
<td>F. Fischbach et al.</td>
<td></td>
</tr>
<tr>
<td>Treatment of Uncomplicated Gonococcal Urethritis in Men with</td>
<td>1642</td>
</tr>
<tr>
<td>Ciprofloxacin 250 mg and 500 mg in One Dose Orally in an Open</td>
<td></td>
</tr>
<tr>
<td>Randomized Study</td>
<td></td>
</tr>
<tr>
<td>M. Tegelberg-Stassen et al.</td>
<td></td>
</tr>
<tr>
<td>The in vitro Activity and Clinical Role of Ciprofloxacin: Observations during Treatment of Patients with Systemic and Urinary Tract Infections Due to Gram-negative Bacilli</td>
<td>1644</td>
</tr>
<tr>
<td>M. F. Parry</td>
<td></td>
</tr>
</tbody>
</table>
Treatment of Severe Complicated Urinary Tract and Tissue Infections with Ciprofloxacin
D. A. Leigh and F. X. S. Emmanuel .......................................................... 1646
Ciprofloxacin versus Placebo in the Treatment of Acute Bacterial Diarrhoea
H. Pichler et al. .............................................................................. 1648
Ciprofloxacin in the Treatment of Chronic Salmonella Carriers
G. Diridl et al. ............................................................................. 1650
Ciprofloxacin Treatment of Infections Caused by Gram-negative Bacilli or Staphylococcus aureus
R. N. Greenberg et al. .......................................................... 1652
Clinical Efficacy and Safety of Oral Ciprofloxacin
R. J. Fass ................................................................................. 1654
The Efficacy and Safety of Ciprofloxacin in Patients with Serious Infections of Selected Tissues
T. M. Nolen et al. ...................................................................... 1656
Efficacy of Ciprofloxacin in the Treatment of Tissue Infections: An Open, Prospective Study
C. R. Mejia et al. ...................................................................... 1658
Clinical and in vitro Evaluation of Ciprofloxacin in the Treatment of Multi-resistant Gram-negative Infections
S. Mehtar et al. ........................................................................ 1660
Distribution Kinetics of Ciprofloxacin for Evaluation of Therapeutic Efficacy in Pseudomonas Bronchopneumonia in Cystic Fibrosis Patients
S. W. Bender et al. .......................................................... 1662
Therapy of Infections with Ciprofloxacin
L. J. Eron et al. ....................................................................... 1664
Ciprofloxacin Therapy in Patients with Pseudomonas Infections
F. Follath et al. ........................................................................ 1666
Ciprofloxacin in the Treatment of Soft Tissue Infections and Osteomyelitis: Pharmacokinetics, Safety and Efficacy
D. E. Nix et al. ........................................................................ 1668
Ciprofloxacin: in vitro Activity and Clinical Use in Osteomyelitis Due to Resistant Organisms
E. S. Johnson et al. .......................................................... 1670
Pilot Study of Ciprofloxacin in the Treatment of Pseudomonas aeruginosa Infection in Cystic Fibrosis
M. E. Hodson et al. .......................................................... 1673
Pseudomonas aeruginosa Infections Treated with Ciprofloxacin
G. A. Pankey et al. .......................................................... 1675
Evaluation of Ciprofloxacin in the Treatment of Severe Infections in Non-neutropenic Patients
F. Parras et al. ........................................................................ 1677
Treatment of Pneumonia with Ciprofloxacin
H. Bassaris et al. .......................................................... 1679
RTI Patients Treated with Ciprofloxacin or Cefalexin: A Randomized Comparison
N. Vetter et al. ...................................................................... 1681
Ciprofloxacin: Efficacy in Eradicating Campylobacter from Marmosets and Pharmacokinetic Data
L. J. Goodman et al. .......................................................... 1683
The Efficacy and Tolerability of Ciprofloxacin in Geriatric Plurimorbid Patients Suffering from Urinary Tract Infection
J. P. Cassiers et al. .................................................................................................................................................. 1685

Ciprofloxacin in the Treatment of Non-complicated Gonococcal Urethritis
L. Belli et al. .............................................................................................................................................................. 1687

Intravenous Treatment of Urinary Tract Infections with Ciprofloxacin and Mezlocillin by a Comparative Clinical Study
H. J. Peters ................................................................................................................................................................. 1689

Ciprofloxacin in the Treatment of Urinary Tract Infections Caused by Pseudomonas aeruginosa and Multiresistant Strains: Initial Report
C. H. Ramirez-Ronda et al. ......................................................................................................................................... 1691

Clinical Efficacy of Ciprofloxacin in Difficult-to-treat Outpatients Suffering from Urinary Tract Infections and Prostatitis
C. Zamfirescu and V. Chysky .................................................................................................................................. 1693

Efficacy and Safety of Ciprofloxacin vs Bactrim (SMZ/TMP) in the Treatment of UTI (PN) Patients: A Randomized Study
R. Schmicker et al. ..................................................................................................................................................... 1695

Clinical, Microbiological and Pharmacokinetic Aspects of Ciprofloxacin in Therapy of Wound Infections after Vascular Surgery
B. Steckmeier et al. .................................................................................................................................................... 1697

Clinical Evaluation of Ciprofloxacin in Bacterial Ocular Infections
M. Ooishi et al. ......................................................................................................................................................... 1699

Ciprofloxacin (BAY o9867): A Clinical Evaluation and Assessment of Its Effect on the Faecal Flora
M. Whitby et al. ......................................................................................................................................................... 1701

*In vitro* Activity of Pefloxacin Alone or in Combination on Multi-resistant Staphylococcus aureus Strains
C. J. Soussy et al. ...................................................................................................................................................... 1703

*In vitro* Bactericidal Activity as a Function of Time of Combinations of Pefloxacin with Aminoglycosides and Pefloxacin with β-Lactam Antibiotics
A. Thabaut et al. ....................................................................................................................................................... 1706

Pefloxacin Concentrations in Sputum and Blood in Patients with Chronic Obstructive Bronchitis
I. Zimmermann et al. .................................................................................................................................................. 1708

Penetration of Pefloxacin in Human Heart Valves
N. Brion et al. ............................................................................................................................................................. 1711

The *in vitro* Activity of Pefloxacin Compared with Three Quinolones, Three Aminoglycosides and Three Cephalosporins against 500 Clinical Isolates
Y. J. Drabu et al. ...................................................................................................................................................... 1713

Pefloxacin Inhibits Multiplication of Legionella pneumophila within Human Macrophages
J. L. Vilde et al. ......................................................................................................................................................... 1715

Pefloxacin as a Substitute for Conventional Therapy in Uncontrolled Staphylococcus aureus Infections
C. J. L. Brun Buisson et al. ..................................................................................................................................... 1717

Treatment of Chronic Osteomyelitis Due to Staphylococcus spp. or Gram-negative Bacteria with a New Quinolone: Pefloxacin
N. Desplaces et al. .................................................................................................................................................... 1719

Single Dose Prophylaxis with Pefloxacin: Serum and Tissue Pharmacokinetics and Clinical Effect in Women Undergoing Hysterectomy
E. E. Petersen et al. .................................................................................................................................................. 1721
Pefloxacin for Treatment of Experimental Legionellosis
E. Dournon et al. .................................................. 1723

Evaluation of Enoxacin Activity against Recent Clinical Isolates
I. Covelli et al. .................................................. 1725

In vitro and in vivo Elimination of Plasmid-borne Antibiotic Resistance by Enoxacin
S. A. Sonstein et al. ............................................. 1727

Enoxacin: Chemotherapeutic Evaluation as a Parenteral and Oral Agent against Hospital-derived Bacteria
C. L. Heifetz et al. ............................................. 1729

Enoxacin vs. Vancomycin Treatment of Methicillin-resistant Staphylococcus aureus Experimental Endocarditis
J. A. Boscia et al. ............................................. 1731

Effect of Food on the Oral Absorption of a Single 400 mg Dose of Enoxacin in Men
A. Somogyi et al. ............................................. 1733

Pharmacokinetics and Penetration of Enoxacin into Sputum
B. R. Dobbs et al. ............................................. 1735

Enoxacin Concentration in Human Prostatic Tissue after Oral Administration
S. Rannikko and A.-S. Malmborg .............................. 1737

Evaluation of Biliary Pharmacokinetics of Oral Enoxacin, a New Quinolone Antibiotic
A. Flowerdew et al. ........................................... 1739

An Open Study of the Safety and Efficiency of Enoxacin (CI919) in Complicated Urinary Tract Infections
G. Williams et al. .............................................. 1741

Clinical and Bacteriological Experiences with Enoxacin Treatment in Urinary Tract Infections in Elderly Patients and Patients under 65 Years
M. Huttunen et al. ............................................ 1743

Enoxacin for the Treatment of Urinary Tract Infection
R. R. Bailey and B. A. Peddie ................................ 1745

Enoxacin in the Treatment of Urinary Tract Infections
R. N. Wyndham et al. ........................................ 1747

Enoxacin: Pharmacokinetics and Therapy of Urological Patients with Complicated Urinary Tract Infections
K. G. Naber et al. ............................................ 1749

A Comparison of Enoxacin and Cephalexin in the Treatment of Patients with Skin and Skin Structure Infections
L. E. King, Jr. and C. G. Vire ................................ 1751

Enoxacin in Bacterial Skin Infection: A Bacteriologically Controlled Clinical Study
H. Mensing ....................................................... 1753

Enoxacin Clinical and Pharmacokinetic Studies in Ear, Nose, and Throat Infections
P. J. Federspil et al. ......................................... 1755

In vitro Efficacy of Ofloxacin against Gram-negative Upper Respiratory Tract Pathogens
D. Isaacson et al. .............................................. 1757

Bactericidal Activity of Ofloxacin in Human Blood
P. M. Shah and C. Jüttner .................................... 1759

Comparative in vitro Activity of Ofloxacin (DL-8280) and Other Antimicrobial Agents against Enteric and Miscellaneous Bacteria
S. Wongwanich et al. ......................................... 1761

Interpretive Criteria for the Agar Diffusion Susceptibility Test with Ofloxacin
K. Grimm and H. Grimm ....................................... 1763
Pharmacokinetics of Ofloxacin in Serum and Skin Blister
T. Kalager et al. .......................................................... 1765
The Concentration of Ofloxacin in Human Prostatic Tissue and Fluid
H. Kumon et al. .......................................................... 1767
Absorption and Excretion of Ofloxacin in Patients with Impaired Renal Function
M. Tsugaya et al. .......................................................... 1769
Ofloxacin: in vitro Activity and Concentrations in Plasma, Urine and Prostatic
Adenoma Tissue in Elderly Patients
K. G. Naber et al. .......................................................... 1771
Ofloxacin: Bactericidal Effect in an in vitro Pharmacokinetic Model
L. Xerri et al. .......................................................... 1773
In vivo Studies with Ofloxacin
W. Ritzerfeld et al. .......................................................... 1775
Ofloxacin: Efficacy in Renal and Subcutaneous Abscess Models in Mice
M. Sato et al. .......................................................... 1777
Comparative in vitro Activity of Ofloxacin, Cefotaxime, Ceftazidime, Gentamicin,
and Netilmicin against 3,965 Clinical Isolates
M. Steinbakk et al. .......................................................... 1780
Antibacterial Activity of Ofloxacin (DL 8280), a New Quinolone Derivative, against
Gram-negative and Gram-positive Bacteria
G. Ravizzola et al. .......................................................... 1781
Pharmacokinetics of Ofloxacin in Humans after Various Single Oral Doses
S. Flor et al. .......................................................... 1783
Pharmacokinetics of Ofloxacin in Humans after a Single 100 mg Dose
and during Multiple 300 mg b.i.d. Administration
S. Flor et al. .......................................................... 1785
Pharmacokinetics of Ofloxacin in Healthy Volunteers after Oral Administration
G. Humbert et al. .......................................................... 1787
Pharmacokinetics of Ofloxacin in Normal Subjects and in Patients with Mild
to Moderate Renal Insufficiency
E. Arosio et al. .......................................................... 1789
Ofloxacin: Clinical and Pharmacokinetic Study in Health and Disease
(Preliminary Data)
S. Vullerini et al. .......................................................... 1791
An Appraisal of Ofloxacin Level in Semen
H. Mizoguchi et al. .......................................................... 1793
Diffusion of Ofloxacin into Human Lung Tissue
L. Couraud et al. .......................................................... 1795
Clinical Experience with Ofloxacin in Severe Hospital Infections
M. Solbiati et al. .......................................................... 1797
Clinical Usefulness of Ofloxacin for the Outpatient with Chronic Respiratory
Tract Infection
Y. Taguchi et al. .......................................................... 1799
Randomized, Comparative Studies of Ofloxacin and Other Standard Treatments
of Urinary and Respiratory Infections
J. Kosmidis et al. .......................................................... 1801
Clinical Evaluation of Ofloxacin in Respiratory and Urinary Tract Infections
A. Lechi et al. .......................................................... 1803
Clinical Experience with Ofloxacin in the Treatment of Various Gram-negative Infections
J. Tsagarakis et al. .................................................. 1805

Efficacy and Safety of Ofloxacin in the Treatment of Urinary Tract Infections in Comparison with Cotrimoxazole and Amoxicillin + Clavulanic Acid
H. Knothe et al. .................................................. 1807

Comparison of Ofloxacin with Co-trimoxazole and Nitrofurantoin in Urinary Tract Infections
P. Porpaczy .................................................. 1809

Efficacy of Ofloxacin on Biliary Tract Infections Compared with Other Drugs
K. Maruyama et al. .................................................. 1811

Efficacy and Tolerance of Ofloxacin in the General Practice
P. M. Shah and W. Stille .................................................. 1813

Efficacy and Safety of Ofloxacin in the Treatment of Urinary Tract Infection
R. Wittenberger et al. .................................................. 1815

Clinical Evaluation of Ofloxacin in Treatment of Non-gonococcal Urethritis
I. Saito .................................................. 1817

Results of Comparative Multicenter Studies with Ofloxacin in Europe
R. Blomer et al. .................................................. 1819

Influence of Sub-minimal Inhibitory Concentrations of Norfloxacin on both Adhesion to Uro-epithelial Cells and Haemagglutinating Activity of Escherichia coli Strains Isolated from Urine
G. Chabanon et al. .................................................. 1821

A Study of Plasmid Stability in the Presence of Subinhibitory Concentrations of Norfloxacin and Novobiocin
A. C. Graham et al. .................................................. 1823

Antibacterial Activity of Norfloxacin and Induction of Resistant Strains
G. Ravizzola et al. .................................................. 1825

Norfloxacin: Worldwide Preclinical Susceptibility Experience of Urinary Tract Pathogens
D. L. Shungu et al. .................................................. 1827

Interaction of Norfloxacin with Nine Other Antibacterial Agents in vitro
B. A. Pelak et al. .................................................. 1829

Efficacy of Norfloxacin in Experimental Models of Urinary Tract and Systemic Infections in Normal and Diabetic Mice: A Comparative Study
R. A. Fromtling et al. .................................................. 1831

Pharmacokinetics of Norfloxacin in Renal Failure
J. P. Fillastre et al. .................................................. 1833

Pharmacokinetic Studies of Norfloxacin in Healthy Volunteers and Effect on the Faecal Flora
D. A. Leigh et al. .................................................. 1835

Experience with Norfloxacin in Oral Treatment of Severe and Complicated Urinary Tract Infections
W. Bischoff .................................................. 1837

Treatment of Acute Bacterial Gastroenteritis with Norfloxacin
J. Sabbaj et al. .................................................. 1839

Efficacy and Tolerance of Norfloxacin in the Treatment of Patients with Complicated Urinary Tract Infections
M. Westenfelder et al. .................................................. 1841
Randomized Comparison of Single-dose vs. Short-term Norfloxacin Therapy in Acute Urinary Tract Infection
E. W. Rugendorff and H.-J. Schneider .......................................................... 1843

Therapeutic Concept with Norfloxacin: Long-term Prophylaxis in Recurrent Cystitis Infections
W. Bischoff ........................................................................................................... 1845

Therapeutic Concept with Norfloxacin: Single Shot Therapy in Acute Cystitis
W. Bischoff ........................................................................................................... 1847

Compassionate Treatments with Norfloxacin
K. Brown and M. Corrado .................................................................................. 1849

Pirfloxacain, a New Florurate Agent
N. Simonetti et al. ................................................................................................. 1851

Efficacy of New Quinolone Compound against Urinary Tract Pathogens
J. Dubois and V. Fontaine .................................................................................... 1855

Susceptibility of Campylobacter spp. to Quinolone Antibacterial Agents
J. Dubois and V. Fontaine .................................................................................... 1857

Ciprofloxacin and Enoxacin Activity vs. Nalidixic Acid, Aminoglycoside-resistant Gram-negative Isolates Alone and with Amikacin or Newer β-Lactams
K. H. Mayer and J. A. Ellal .................................................................................. 1859

Activity of the 4-Quinolone Antibacterials at Physiological pH Values
J. T. Smith and N. T. Ratcliffe .............................................................................. 1861

In vitro Activity of 4-Quinolones against Difficult-to-treat Organisms and Development of Resistance to These Drugs
F. H. Kayser and G. Morenzoni ........................................................................... 1863

Research for a Hierarchy in the Acquisition of Resistance to the Quinolones
H. B. Drugeon et al. .............................................................................................. 1865

Growth Deficiency of Quinolone-resistant Mutants
P. Courvalin et al. .................................................................................................. 1867

Quantitative Analysis of Spontaneous Mutations in Serratia marcescens Which Affect Susceptibility to Quinolones in Different Ways
I. Haller ................................................................................................................ 1869

Bactericidal Activity of Ciprofloxacin, Norfloxacin and Ofloxacin in Serum and Urine after Oral Administration in Healthy Volunteers
H.-J. Zeiler et al. .................................................................................................... 1871

In vitro Antibacterial Activities of Seven Quinolones
K. T. Luh et al. ....................................................................................................... 1873

Comparative Activities of Ciprofloxacin, Ticarcillin, and Tobramycin against Experimental Pseudomonas aeruginosa Pneumonia
J. Pennington et al. ............................................................................................... 1875

Comparative Activities of Five Antimicrobial Agents in Experimental Proteus Pyelonephritis
P. G. H. Peerbooms and D. M. MacLaren .......................................................... 1877

Comparative Activities of AM-833, Norfloxacin, Ciprofloxacin and Ofloxacin against Various Experimental Infections
K. Hirai et al. ......................................................................................................... 1879

Antimicrobial Activity of Quinolone Antibiotics in Urine
T. Kumada et al. ..................................................................................................... 1881

Susceptibility to Quinolones in Relation to Other Antimicrobial Agents
M. S. M. Daniëls .................................................................................................... 1883
In vitro Activity of Ciprofloxacin, Pefloxacin and Ofloxacin against Legionella
A. Buré et al. ............................................................................................................. 1885

Susceptibility of Amikacin-resistant Strains of Pseudomonas to Ciprofloxacin and Norfloxacin
C. R. Rivera-Vázquez et al. .................................................................................. 1887

Isolation of Mutants of Pseudomonas aeruginosa PA01 Resistant to Ciprofloxacin, Norfloxacin and Ofloxacin and Incomplete Cross-resistance with Nalidixic Acid
P. Campos et al. ........................................................................................................ 1889

The Pharmacokinetics and Saliva Penetration of Ofloxacin, Norfloxacin, Enoxacin and Pipemidic Acid
M. Uematsu et al. ..................................................................................................... 1891

A Comparison of the Pharmacokinetics and Tissue Penetration of Ciprofloxacin (Oral and i.v.) and Ofloxacin (Oral) Administered to Volunteers, and Comparison with in vitro Activity
R. Wise et al. ............................................................................................................. 1893

Contents of Antimicrobial Section 1
Special Lecture ........................................................................................................... 1
Symposia ................................................................................................................... 11
§ 1. New Antimicrobial Agents, Microbiology and Biochemistry ......................... 235
§ 2. Diagnostics and Susceptibility .......................................................................... 431
§ 3. Pharmacokinetics .............................................................................................. 623
§ 4. Experimental Infection ...................................................................................... 747
§ 5. Immunology ....................................................................................................... 789

Contents of Antimicrobial Section 3
§ 11. Miscellaneous Antimicrobial Agents ................................................................. 1895
§ 12. Internal Medicine and Pediatrics ................................................................... 1979
§ 13. Urology ........................................................................................................... 2185
§ 14. Surgery, Gynecology and Obstetrics ................................................................. 2319
§ 15. Miscellaneous Infections .................................................................................. 2525
§ 16. Adverse Side Effects ........................................................................................ 2595
§ 17. Antibiotic Policy ............................................................................................... 2677
Workshop Summaries .............................................................................................. 2701
Author Index ........................................................................................................... 2793
Subject Index ........................................................................................................... 2829
Disease/Pathogen Index .......................................................................................... 2834
Compound Index .................................................................................................... 2838
Abbreviations of Antimicrobial Agents .................................................................. 2843